按行业排序
2013
10/25/21

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

阅读更多
10/19/21

Castle Biosciences收购cernostic

阅读更多
8/22/21

太阳能在乔治亚州蓬勃发展，那里没有强制要求

阅读更多
6/15/21

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

阅读更多
4/30/21

BILLION-DOLLAR RANCH HANDS: How Silicon Ranch became a homegrown powerhouse

阅读更多
4/27/21

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

阅读更多
3/2/21

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

阅读更多
2/12/21

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

阅读更多
12/22/20

2021年最值得买入的21只股票

阅读更多
12/18/20

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

阅读更多
12/15/20

Silicon Ranch与现有股东完成2.25亿美元股权融资

阅读更多
12/9/20

G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium

阅读更多
11/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

阅读更多
10/8/20

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

阅读更多
9/2/20

Castle Biosciences宣布DecisionDx-SCC上市

阅读更多
6/24/20

城堡生物科学宣布定价为74美元.2亿普通股公开发行

阅读更多
4/13/20

Orig3n Receives FDA Emergency Use Authorization (EUA) For Coronavirus 2019 Test

阅读更多
11/19/19

Silicon Ranch签约Facebook在乔治亚州的107兆瓦太阳能项目

阅读更多
10/29/19

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

阅读更多
10/7/19

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma

阅读更多
7/29/19

Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

阅读更多
6/26/19

Silicon Ranch推出再生能源™

阅读更多
6/18/19

G1 THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN WOMEN WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER

阅读更多
3/6/19

独立展望出版物, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction

阅读更多
2/20/19

Clearside Receives Notification of FDA Acceptance of NDA Filing for XIPERE

阅读更多
2/7/19

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

阅读更多
1/30/19

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

阅读更多
1/7/19

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

阅读更多
12/6/18

Castle Biosciences宣布任命基因组健康首席财务官G. Bradley Cole加入董事会

阅读更多
12/5/18

硅谷农场将为Facebook在乔治亚州的数据中心提供电力

阅读更多
10/18/18

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

阅读更多
7/30/18

Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

阅读更多
5/31/18

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

阅读更多
5/23/18

歌公司. 获得Aspire健康

阅读更多
4/16/18

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

阅读更多
3/28/18

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

阅读更多
3/15/18

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer

阅读更多
3/5/18

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

阅读更多
1/22/18

壳牌收购美国太阳能开发公司硅牧场的主要股份

阅读更多
1/22/18

壳牌收购硅牧场公司

阅读更多
12/18/17

G1 Therapeutics加入Nasdaq生物科技指数

阅读更多
9/18/17

G1疗法加入罗素2000®，3000®和Microcap®指数

阅读更多
7/13/17

G1 Therapeutics任命Andrew Witty爵士为董事会成员

阅读更多
6/9/17

Myomo公司. 完成历史性的首次公开发行

阅读更多
5/30/17

G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting

阅读更多
3/29/17

G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

阅读更多
1/10/17

G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer

阅读更多
11/2/16

AgTech Accelerator Corporation Announces the Addition of 彩乐园2 Pioneer Elanco to Blue-Chip Investor Syndicate; Completes $20 Million First Closing

阅读更多
9/21/16

NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis

阅读更多
6/1/16

Clearside生物医学公司. 宣布首次公开发行的定价

阅读更多
5/11/16

G1公司获得4700万美元C轮融资

阅读更多